Manuscript Title:

Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States

Authors:

Patricia C. Lloyd, PhD, ScM,¹ Elizabeth R. Smith, BS,² Joann F. Gruber, PhD, MSPH,¹ Michelle Ondari, MSPH,² Hui Lee Wong, PhD,¹ Mao Hu, BS,² Tainya C. Clarke, PhD, MPH, MSc,¹ Rowan McEvoy, BS,² Kandace L. Amend, PhD, MPH,³ Daniel C. Beachler, PhD, MHS,⁴ Cheryl N McMahill-Walraven, PhD, MSW,⁶ John D. Seeger, DrPH, PharmD,³ Alex Secora, PhD,⁵ Djeneba Audrey Djibo, PhD,⁶ Jennifer Song, MA, MURP,³ Nandini Selvam, PhD, MPH,⁵ Jonathan P. DeShazo, PhD, MPH,⁶ Robin Clifford, MS,³ Eugenio Abente, PhD,⁶ Yoganand Chillarige, MPA,² Richard A. Forshee, PhD,¹ Steven A. Anderson, PhD, MPP,¹ Azadeh Shoaibi, PhD, MHS.⁷

Affiliations:

- ¹ US Food and Drug Administration, Silver Spring, MD, USA
- ² Acumen LLC, Burlingame, CA, USA
- ³ Optum Epidemiology, Boston, MA, USA
- ⁴Carelon, Wilmington, DE, USA
- ⁵ IQVIA, Falls Church, VA, USA

18 ⁶CVS Health Clinical Trial Services, Blue Bell, PA, USA

- ¹⁹ ⁷ Affiliated with the US Food and Drug Administration, Silver Spring, MD, USA during the conduct of this work
- 20

21 Author Email Addresses:

- 22 Patricia C. Lloyd (patricia.lloyd@fda.hhs.gov), Elizabeth R. Smith (esmith@acumenllc.com), Joann F. Gruber
- 23 (joann.gruber@fda.hhs.gov), Michelle Ondari (mondari@acumenllc.com), Hui Lee Wong (huilee.wong@fda.hhs.gov), Mao Hu
- 24 (mhu@acumenllc.com), Tainya C. Clarke (tainya.clarke@fda.hhs.gov), Rowan McEvoy (rmcevoy@acumenllc.com), Kandace L.
- 25 Amend (kandace.amend@optum.com), Daniel C. Beachler (daniel.beachler@carelon.com), Cheryl N McMahill-Walraven
- 26 (cheryl.walraven@cvshealth.com), John D. Seeger (john.seeger@optum.com), Alex Secora (alex.secora@iqvia.com), Djeneba
- 27 Audrey Djibo (audrey.djibo@cvshealth.com), Jennifer Song (jennifer.song@optum.com), Nandini Selvam
- 28 (nandini.selvam@iqvia.com), Jonathan P. DeShazo (jonathan.deshazo@cvshealth.com), Robin Clifford (robin.clifford@optum.com),
- 29 Eugenio Abente (abentee@aetna.com), Yoganand Chillarige (ychillarige@acumenllc.com), Richard A. Forshee
- 30 (richard.forshee@fda.hhs.gov), Steven A. Anderson (steven.anderson@fda.hhs.gov), Azadeh Shoaibi (azadeh.shoaibi@nih.gov).
- 31
- 32 Corresponding Author:
- 33 Patricia C. Lloyd, PhD, ScM
- 34 Health Statistician

- 35 Office of Biostatistics and Pharmacovigilance
- 36 Center for Biologics Evaluation and Research
- 37 U.S. Food & Drug Administration
- 38 10903 New Hampshire Ave., Building 71
- 39 Silver Spring, MD 20993
- 40 Email: patricia.lloyd@fda.hhs.gov
- 41 Word Count: 2,957

43 Keywords

44 COVID-19 vaccine, vaccine safety, SARS-CoV-2, bivalent COVID-19 vaccine, mRNA vaccines

45 Abstract (Word Count: 299/300)

46 **Importance**

47 Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes post-licensure.

48 **Objective**

- 49 To evaluate health outcomes following bivalent COVID-19 Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273.222)
- 50 vaccination among individuals 6 months and older in the United States.
- 51 **Design**
- 52 Monthly monitoring of health outcomes from August 2022 to July 2023 in four administrative claims databases. Descriptive analyses
- 53 monitored vaccine uptake, outcome counts and coadministration of bivalent COVID-19 and influenza vaccines. Sequential analyses
- 54 tested for elevated risk of each outcome in a prespecified post-vaccination risk interval, or a period of hypothesized elevation based on
- 55 clinical guidance, compared to a historical baseline.

56 Participants and Exposures

- 57 Persons 6 months and older who received a bivalent COVID-19 BNT162b2 or mRNA-1273.222 vaccine during the study period, with
- 58 continuous enrollment in a medical insurance plan from the start of an outcome-specific clean interval to the COVID-19 vaccination
- 59 date. Vaccines were identified using product-specific codes from medical coding systems.
- 60 Health Outcomes

- 62 months-5 years. Twenty-one outcomes were monitored in BNT162b2 vaccine recipients 5-17 years and mRNA-1273.222 vaccine
- 63 recipients 6-17 years. Eighteen outcomes were monitored in persons 18 years and older for both mRNA vaccines.
- 64 **Results**
- 65 Overall, 13.9 million individuals 6 months and older received a single bivalent COVID-19 mRNA vaccine. The statistical threshold
- 66 for a signal was met for two outcomes in one database: anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccines in
- 67 persons 18-64 years and myocarditis/pericarditis following bivalent BNT162b2 vaccines in individuals 18-35 years. There were no
- 68 signals identified in young children.
- 69 Conclusions
- 70 Results were consistent with prior observations from published studies on COVID-19 vaccine safety. This study supports the safety
- 71 profile of bivalent COVID-19 mRNA vaccines and the conclusion that the benefits of vaccination outweigh the risks.

72 1. Background

The U.S. Food & Drug Administration (FDA) first authorized bivalent formulations of COVID-19 mRNA vaccines in August 73 2022.¹ These updated vaccines included both the SARS-CoV-2 ancestral strain and omicron BA.4 and BA.5 subvariants and offered 74 added protection against more recently circulating strains of the virus.¹ Vaccines were first authorized in persons 12 years and older 75 76 for the bivalent COVID-19 Pfizer-BioNTech (BNT162b2) vaccine, and 18 years and older for the bivalent COVID-19 Moderna (mRNA-1273.222) vaccine.^{2,3} The authorization for both vaccine brands was expanded in October 2022 to include persons 5 years 77 and older for the bivalent BNT162b2 vaccine and 6 years and older for the mRNA-1273.222 vaccine.^{2,3} In December 2022, the 78 authorization for both vaccine brands was further expanded to include populations 6 months and older.^{2,3} 79 There have been approximately 56 million bivalent COVID-19 vaccine doses administered in the U.S. as of May 2023.⁴ Of these, 80 81 42.0% have been administered to persons 65 years and older, 51.9% to persons aged 18-64 years, 5.9% to persons aged 5-17 years, and <1% to the population aged 6 months- 4 years.⁴ Overall, bivalent COVID-19 mRNA vaccines have been administered to about 82 83 17.0% of the U.S. population.⁴ 84 FDA has been performing near real-time surveillance to monitor the real-world safety of bivalent COVID-19 vaccines available in 85 the U.S. Near real-time surveillance is a screening method designed to rapidly identify potential safety signals as vaccines are administered. However, results do not establish a causal association due to methodologic limitations. More robust epidemiological 86 87 studies may be used to evaluate potential safety signals identified from screening methods.

This study presents results from FDA's near real-time safety monitoring of bivalent COVID-19 vaccines using data from three commercial databases representing vaccine recipients aged 6 months to 64 years, and the Centers for Medicare & Medicaid Services (CMS) Medicare database representing vaccine recipients aged 65 years and older.

91 **2.** Methods

92 2.1 Data Sources

This study used administrative commercial health claims data from Carelon Research, CVS Health, and Optum to capture health 93 care data on the population aged 6 months - 64 years old. Medicare Fee-For-Service (FFS) data from the CMS Shared Systems 94 95 Database was used to capture data on the population aged 65 years and older. These databases contain longitudinal medical and pharmacy claims data that captures patient's demographic information, clinical diagnoses, and vaccine administration information 96 97 among other health care utilization information. The CMS Medicare enrollment database was used to capture enrollment information for the Medicare population. Where available, local and state-based Immunization Information Systems (IIS) data was linked to 98 99 commercial claims databases to supplement the capture of patient's COVID-19 vaccination history. Once validated, data from select 100 IIS jurisdictions was included in the analysis. Supplementary Table E1 summarizes individual database-related characteristics 101 including enrollment size and claims delay. 102

104 **2.2 Study Population and Period**

105 Health plan members aged 6 months and older were included in surveillance if they received a bivalent COVID-19 mRNA vaccine 106 during the vaccine brand- and age-specific authorization periods and were continuously enrolled in their respective health plan for the 107 complete duration of the outcome-specific clean interval. The surveillance period extended from the U.S. authorization date for the bivalent COVID-19 mRNA vaccines (i.e., August 2022 for ages 12 years and older; October 2022 for 5-11 years of age; December 108 109 2022 for 6 months to 4 years of age) through mid-2023. Exact surveillance start dates varied by vaccine brand and age group based on 110 vaccine authorization dates (Supplementary Table E2). 2.3 Exposures and Follow-Up 111 112 The exposure was defined as the receipt of the bivalent BNT162b2 or mRNA-1273.222 COVID-19 vaccines in any setting during 113 the vaccine brand and age-specific authorization periods. Bivalent COVID-19 mRNA vaccines were identified in claims and IIS data using product and dose-specific codes from the Current Procedural Terminology (CPT)/ Health Care Common Procedure Coding 114 115 System (HCPCS), National Drug Codes (NDCs), and CVX (vaccine administered) codes.⁵ Only individuals' first bivalent vaccine 116 administration was included in surveillance because bivalent COVID-19 vaccines were authorized as a single dose at the start of 117 surveillance.

Follow-up time included all person-time accrued during the prespecified post-vaccination risk intervals. Risk intervals were defined as a period of hypothesized elevated risk due to vaccination and were established based on guidance from clinicians and literature review. Risk intervals were censored at disenrollment, subsequent COVID-19 vaccination, surveillance end date, or death.

121 **2.4 Health Outcomes**

122 Health outcomes were selected based on literature review, consultation with clinicians, and prior COVID-19 vaccine surveillance 123 activities. Outcomes were monitored separately: an individual with multiple different outcomes was included in surveillance for each outcome, but only the first eligible occurrence of an outcome was included in the analysis. Eligible outcomes were defined as those 124 125 occurring in the risk interval with no prior occurrence of the respective outcome during the outcome-specific clean interval. The clean 126 interval was a period defined relative to vaccination date used to identify incident outcomes, in which an individual enters the 127 outcome-specific study cohort only if the outcome did not occur during this interval. Table 1 presents the outcomes with clinical care 128 settings, risk intervals, and clean intervals used to identify incident outcomes. It also indicates outcomes that were included in 129 descriptive monitoring and sequential testing, by age group. 130 While most outcomes underwent sequential testing, outcomes were only descriptively monitored if there were limited historical 131 case counts to estimate background rates, which were required for testing. Among children aged 6 months -4 years and 6 months -5132 years receiving BNT162b2 and mRNA-1273.222 vaccines respectively, 12 outcomes underwent descriptive monitoring and sequential 133 testing, while eight were only descriptively monitored. For persons 5-17 years and 6-17 years receiving BNT162b2 and mRNA-

1273.222 vaccines respectively, 13 outcomes were both descriptively monitored and sequentially tested, and eight outcomes were only
descriptively monitored. Seventeen outcomes were included in descriptive monitoring and sequential testing for adults 18 years and
older, while a single outcome was only descriptively monitored (Table 4).

137 2.5 Statistical Analyses

138 Descriptive Monitoring

139 Vaccine uptake and health outcome counts were monitored monthly along with the demographic characteristics of vaccine

140 recipients. The frequency of concomitant bivalent COVID-19 and seasonal influenza vaccination was also monitored. Prevalence of

141 concomitant influenza vaccination was measured on the same-day and within 42 days prior to or following the bivalent COVID-19

142 mRNA vaccination date. Concomitant influenza vaccination was only descriptively monitored and was not included in inferential

143 testing nor adjusted for in any analyses.

144 Sequential Testing

145 The Poisson Maximized Sequential Probability Ratio Test (PMaxSPRT) was used to evaluate the rate of outcomes in specific age

146 groups following vaccination compared to a historical baseline rate.⁶ Monthly sequential testing was performed to generate incidence

147 rate ratios (IRRs) of observed outcome rates compared with database-specific historical (expected) rates. Historical rates were

148 adjusted to account for claims processing delay, and where case counts permitted, standardized by age and sex for the population

149 younger than 65 years old, and by age, sex, race, and nursing home residency for the population 65 years and older.⁷ We estimated

150 annual historical rates for a pre-COVID-19 period (2017-2019) and a COVID-19 period between April and December 2020. Selection 151 of the comparator rate was based on the overlap between the 95% confidence intervals for the periods. If rates in the historical period 152 (individual years between 2017 and 2020) did not have overlapping 95% confidence intervals indicating a substantive difference in the 153 rates, we selected the lower or more stable rate as the most conservative approach. This was performed to enhance the sensitivity of 154 the test by increasing the likelihood that potential signals were not missed. Otherwise, the median annual rate was selected. Pre-155 COVID-19 rates from 2019 were selected for most outcomes; however, rates from the 2020 COVID-19 period were selected if the 156 COVID-19 period rates did not return to pre-COVID-19 levels. 157 For each outcome, monthly sequential testing was conducted in each database and began when a minimum of three outcomes after bivalent COVID-19 vaccination was observed. Testing was conducted until the earlier of one of the following events occurred: an 158 159 observed signal, surveillance end, or when the outcome-specific prespecified surveillance length was met, which was defined as the expected number of outcomes within a 6-month period.⁵ We used a one-tailed test with a null hypothesis that the observed outcome 160 rate was no greater than the historical comparator beyond a prespecified test margin with an overall alpha of 1%. A strict alpha level 161 162 was selected to minimize false signals based on the large number of tests performed. Testing margins were determined for each 163 outcome based on input from clinicians to avoid detection of minimal increases in risk that were unlikely to be clinically relevant. A statistical signal occurred if the log likelihood ratio exceeded the critical value, which was a threshold set to determine if the observed 164 result was due to chance.⁵ SAS © version 9.4, R version 4.1.2, and R Sequential Package Version 3.3.1 were used for the analysis. 165

166 This surveillance activity was performed under the FDA Biologics Effectiveness and Safety (BEST) Initiative and is covered 167 under the scope of the FDA public health surveillance mandate.

168 **3. Results**

169 Descriptive Monitoring

170 A total of 13.9 million bivalent COVID-19 mRNA vaccine doses were observed, including 5.5 million vaccinations across

171 commercial databases including Carelon Research, CVS Health, and Optum databases, and 8.4 million vaccinations in the Medicare

172 FFS database (Table 2). Figure 1 shows weekly vaccine uptake by vaccine brand and database. Among commercial databases, Carelon

173 had the highest weekly vaccine uptake compared to CVS Health and Optum databases. Figure 2 shows weekly vaccine uptake in

174 commercial and Medicare databases by vaccine brand and age group. For adults 18 years and older, peak vaccination uptake occurred

175 between September and December 2022, with the highest weekly vaccination uptake observed for persons 65 years and older. For

176 children 5-17 years, BNT162b2 vaccine recipients had the highest weekly vaccine uptake between September and December 2022.

177 Minimal weekly vaccine uptake was observed for BNT162b2 and mRNA-1273.222 vaccine users 6 months-4 years and 6 months-5

178 years respectively, and mRNA-1273.222 vaccine users 6-17 years.

Among vaccine recipients 6 months-64 years in commercial insurance databases, 12% were 6 months-17 years, 24% were 18-35

180 years, 39% were 36-55 years, and 25% were 56-64 years (Table 2). There was a slightly higher proportion of female recipients (54%)

181 than males, which was consistent for BNT162b2 and mRNA-1273.222 vaccine brands. The majority of vaccine users resided in urban

areas (95%). The prevalence of same-day concomitant bivalent COVID-19 and seasonal influenza vaccination was 40%, increasing to 182 183 62% in the 42 days prior to or after the COVID-19 vaccination date. There was a slightly higher proportion of same-day concomitant vaccination among BNT162b2 recipients (41%) than mRNA-1273.222 recipients (39%), increasing to 62% for both vaccine brands in 184 185 the 42 days before or after bivalent COVID-19 vaccination (Table 2). In the Medicare FFS population 65 years and older, 88% of vaccine recipients were aged 65-84 years with a higher proportion of 186 187 females (57%) than males. This was relatively consistent across BNT162b2 and mRNA-1273.222 vaccine users (Table 2). The 188 majority of COVID-19 vaccine users resided in urban areas (82%), with a slightly higher proportion of BNT162b2 vaccine users 189 residing in urban areas (85%) compared to mRNA-1273.222 users (79%). Only a small portion of vaccine users resided in the nursing 190 home (2%). The prevalence of same-day concomitant bivalent COVID-19 and seasonal influenza vaccination was 33%, increasing to 191 72% in the 42 days before or after bivalent COVID-19 vaccination. There was a higher rate of same-day concomitant vaccination with 192 influenza vaccines among BNT162b2 vaccine users (35%) compared to mRNA-1273.222 users (30%), increasing to 73% and 70% 193 respectively in the 42 days prior to or following COVID-19 vaccination. 194 Sequential Testing

195 Sequential testing was performed for outcomes with estimable background rates. Of 17 outcomes monitored with sequential

196 testing in adults aged 18-64 years, anaphylaxis and myocarditis/pericarditis met the statistical threshold for a signal in one of three

197 databases (Table 3). An anaphylaxis signal was detected following bivalent BNT162b2 and mRNA-1273.222 vaccination among

participants aged 18-64 years in the Carelon Research database, based on <11 events¹ for each vaccine brand. Similarly, a 198 199 myocarditis/pericarditis signal was observed among bivalent BNT162b2 vaccine recipients aged 18-35 years in the Carelon Research database, based on <11 events¹. No statistical signals were observed in CVS Health, Optum, or Medicare FFS databases. 200 201 The incidence rate of anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccination was 74.5 and 109.4 cases per 100,000 person-years respectively, among those 18-64 years in the Carelon database. The incidence rate of myocarditis/pericarditis 202 203 following bivalent BNT162b2 vaccination was 131.4 cases per 100,000 person-years for persons 18-35 years in the Carelon database. 204 Among the population aged 6 months-4 years and 6 months-5 years receiving the bivalent COVID-19 BNT162b2 and mRNA-205 1273.222 vaccines, respectively, sequential testing was not initiated for any of the 12 outcomes for which testing was planned, as the 206 minimum number of cases needed to start testing (i.e., 3 cases) was not observed. Similarly, for the population aged 5-17 years, of 13 207 outcomes included in testing, testing was only initiated for appendicitis, seizures/convulsions, and Bell's Palsy following BNT162b2 208 vaccination across commercial databases due to limited case counts for the other outcomes. Testing was not initiated for any outcomes among mRNA-1273.222 vaccine recipients aged 5-17 years due to limited case counts. The majority of outcomes did not initiate 209 210 testing in persons 6 months-17 years due to limited case counts. Of outcomes that initiated testing in this age group, no statistical 211 signals were detected for either vaccine brand (Table 3). 212 In the Medicare population aged 65 years and older, sequential testing was initiated for all 17 outcomes for both BNT162b2 and

²¹³ mRNA-1273.222 vaccinations, and no statistical signals were detected (Table 3).

¹ Cell counts < 11 have been suppressed in the manuscript text and tables.

214 **4. Discussion**

This study monitored the safety of bivalent COVID-19 mRNA vaccines administered to 13.9 million persons 6 months and older 215 216 in the U.S. by evaluating the risk of several outcomes following vaccination. Two outcomes met the statistical threshold for a signal in 217 one of three commercial databases: anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccination in recipients aged 218 18-64 years and myocarditis/pericarditis following BNT162b2 vaccination in recipients aged 18-35 years. 219 These findings are largely consistent with existing safety assessments of COVID-19 mRNA vaccines. An elevated risk of myocarditis/pericarditis and anaphylaxis was identified following monovalent mRNA vaccines.⁸⁻¹² Risk of myocarditis/pericarditis 220 was specifically identified in males aged 12-39 years of age in other studies.^{8,10,12} While an increased anaphylaxis risk has been 221 reported,^{9,11,13} more recent studies have suggested a comparable risk to that of other vaccines.¹⁴ Surveillance for the bivalent COVID-222 223 19 mRNA vaccines by the Vaccine Adverse Event Reporting System (VAERS) has similarly shown cases of myocarditis/pericarditis and allergic/anaphylactic events among the population aged 12 years and older.¹⁵ A prior near-real time surveillance study identified a 224 statistical signal for seizures/convulsions following monovalent BNT162b2 and mRNA-1273 vaccination in children 2-4/5 years.¹⁶ 225 Our study identified zero cases of seizures/convulsions in this age group following bivalent vaccination, and no outcomes met the 226 227 statistical threshold for signal in the young age group. Our study population had a high prevalence of same-day concomitant administration of bivalent COVID-19 mRNA and influenza 228 229 vaccines. Clinical trials that have assessed the safety and reactogenicity of concomitant administration of these vaccines have not found any safety concerns or reduced immune response related to the concomitant use of these vaccines.¹⁷⁻¹⁹ While we had a high 230

231	prevalence of concomitant vaccination, our study did not perform testing stratified by concomitant influenza vaccination status; thus,
232	we are unable to draw any conclusions about the safety of concomitant vaccination.
233	This study had several strengths. The study included a large sample size of geographically diverse participants from all age groups
234	authorized to receive bivalent BNT162b2 or mRNA-1273.222 vaccines from both commercially and publicly insured populations
235	across the U.S. The study also evaluated several outcomes as vaccines were administered. The near-real time surveillance method
236	allowed for vaccine safety to be monitored shortly after bivalent COVID-19 mRNA vaccine authorizations. Outcomes were similarly
237	able to be monitored for an extensive period varying from three to eleven months depending on database, vaccine brand and age
238	group.
239	The near-real time surveillance method applied in this study is a crude signal detection method used for rapid safety screening.
240	This method uses a comparator (i.e., aggregate historical rates) with limited adjustment for confounding factors. This method,
241	similarly, requires the specification of multiple parameters that, if misspecified, could affect the presence or absence of detected
242	signals such as risk interval timing and length, and the testing margin used to identify meaningful elevations in risk. Additionally, we
243	did not adjust for multiple testing of outcomes which may have increased the likelihood of observing a false positive safety signal
244	when risk is not truly elevated. Therefore, this method does not establish a causal association between the vaccines and outcomes.
245	Furthermore, although we observed substantial uptake of bivalent COVID-19 mRNA vaccines, this was reduced relative to
246	administration of monovalent COVID-19 mRNA vaccine doses. This could have decreased our power to detect statistical signals,
247	particularly for rare outcomes, and may explain some differences in signals detected or not detected across databases. Our study was

248	also limited by the use of administrative claims data, collected for billing purposes, but used for safety surveillance activities. Our
249	medical record review has shown that certain outcomes are detected in claims data more accurately than others. ^{20,21} Since we did not
250	conduct medical record review nor adjust for outcome misclassification for outcomes evaluated in this study, the presence and extent
251	of outcome misclassification is unknown and could apply to at least some of the outcomes included in surveillance. This can bias
252	signal detection in either direction.
253	The surveillance of bivalent COVID-19 mRNA vaccines supports the safety of these vaccines and is consistent with findings from
254	surveillance results of monovalent COVID-19 mRNA vaccines. This study contributes to regulatory decision-making for COVID-19
255	vaccines and public health and supports the conclusion that the benefits of vaccination outweigh the risks.

- 257 All authors attest they meet the ICMJE criteria for authorship.
- 258

259 Conflicts of Interest Statement

- 260 Co-authors from U.S. Food and Drug Administration and Acumen LLC declared no conflicts of interests. The following authors
- 261 reported a conflict of interest: Kandace L. Amend, ¹ John D. Seeger, ¹ Jennifer Song, ¹ Robin Clifford, ¹ Cheryl N. McMahill-
- 262 Walraven,² Djeneba Audrey Djibo,² Jonathan P. DeShazo,² Eugenio Abente,² Daniel C. Bleacher,³ Alex Secora,⁴ Nandini Selvam.⁴
- ¹Employee of Optum, with reported stock or stock options in UnitedHealth Group.
- ²Employee of CVS Health.
- ³Employee of Elevance Health Incorporated.
- ⁴Employee of IQVIA.
- 267

268 Acknowledgements

- 269 We would like to thank Bowen Chen, Yue Wu, Vincent Varvaro, Kamran Kazemi, Olivia Zhang, Nimesh Shah, Samikshya Siwakoti,
- 270 Anchi Lo, Jing Wang, Bing Lyu from Acumen LLC; Grace Yang, Sarah Sargen, Alexandra Stone, Wafa Tarazi, Megan Ketchell,
- 271 Kathryn Federici, Amaka Ume, Emily Myers, Eli Wolter, Jackson Slaney, Bobby Smith, Lauren Peetluk, and Elizabeth Bell from
- 272 Optum; Anne Marie Kline, Nancy B. Shaik, Ana M. Martinez-Baquero, Smita Bhatia, Vaibhav Sharma from CVS; Shiva Vojjala,

273 Ramya Avula, Shiva Chaudhary, Shanthi P Sagare, Ramin Riahi, Brian Greenwald, and Grace Stockbower, Michael Goodman,

- 274 Michael Bruhn, and Ruth Weed from Carelon/IQVIA.
- 275

276 Funding

- 277 This work was supported by the U.S. Food and Drug Administration, whom were an integral part of the study design, implementation
- and interpretation of the analysis, writing of the report, along with the decision to submit the manuscript for publication.

280 **References**

- Administration FaD. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19
 Vaccines for Use as a Booster Dose. 2022; <u>https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-</u>
 update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use, 2023.
- 284 2. U.S. Food and Drug Administration. Moderna COVID-19 Vaccine (2023-2024) Letter of Authorization. In:2023.
- 285 3. U.S. Food and Drug Administration. Letter of Authorization (Reissued). In:2023.
- 286 4. Centers for Disease Control and Prevention. COVID-19 Vaccination in the United States. 2023; <u>https://covid.cdc.gov/covid-</u>
 287 <u>data-tracker/#vaccinations_vacc-people-booster-percent-pop5</u>, 2023.
- Center for Biologics Evaluation and Research BI. COVID-19 Vaccine Safety Surveillance: Bivalent Dose Vaccine Active Monitoring Protocol Addendum 2023; <u>https://bestinitiative.org/wp-content/uploads/2023/01/C19-Bivalent-Booster-Active-</u> Monitoring-Protocol-Addendum-2022.pdf. Accessed 2023.
- Kulldorff M, Davis RL, Kolczak† M, Lewis E, Lieu T, Platt R. A Maximized Sequential Probability Ratio Test for Drug and
 Vaccine Safety Surveillance. *Sequential Analysis*. 2011;30(1):58-78.
- Center for Biologics Evaluation and Research BI. Background Rates of Adverse Events of Special Interest for COVID-19
 Vaccine Safety Monitoring. 2021; <u>https://bestinitiative.org/wp-content/uploads/2022/01/C19-Vax-Safety-AESI-Bkgd-Rate-</u>
 <u>Protocol-FINAL-2020.pdf</u>, 2023.
- 8. Fatima M, Ahmad Cheema H, Ahmed Khan MH, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. *Annals of medicine and surgery (2012)*. 2022;76:103486.
- McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. *The Journal of allergy and clinical immunology*. 2016;137(3):868-878.
- 30010.Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From301December 2020 to August 2021. JAMA. 2022;327(4):331-340.
- 302 11. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December
 303 14, 2020-January 18, 2021. *JAMA*. 2021;325(11):1101-1102.
- 304 12. Goddard K, Lewis N, Fireman B, et al. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19
 305 vaccination. *Vaccine*. 2022;40(35):5153-5159.
- Judd A, Samarakoon U, Blumenthal K. Self-Reported Reactions After COVID-19 Vaccination. *Journal of Allergy and Clinical Immunology*. 2022;149(2):AB56.
- Jaggers J, Wolfson AR. mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation. *Current allergy and asthma reports*. 2023;23(3):195-200.
- Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among
 Persons Aged ≥12 Years United States, August 31-October 23, 2022. *MMWR Morbidity and mortality weekly report*.
 2022;71(44):1401-1406
- 312 2022;71(44):1401-1406.

Hu M, Shoaibi A, Feng Y, et al. Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years. 2023:2023.2010.2013.23296903.

- Hause AM, Zhang B, Yue X, et al. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in
 the US. *JAMA network open*. 2022;5(7):e2222241.
- 31718.Izikson R, Brune D, Bolduc J-S, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered318concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥ 65 years: a phase 2, randomised,319open-label study. *The Lancet Respiratory Medicine*. 2022;10(4):392-402.
- Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines
 (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised,
 controlled, phase 4 trial. *Lancet (London, England)*. 2021;398(10318):2277-2287.
- Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza
 vaccination of Medicare beneficiaries. *Vaccine*. 2019;37(43):6543-6549.
- Goud R, Thompson D, Welsh K, et al. ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis
 incidence in Medicare. *Vaccine*. 2021;39(38):5368-5375.
- Al Qudah Z, Abukwaik W, Souayah N. Stroke after Vaccination in United States. A Report from the CDC/FDA Vaccine
 Adverse Event Reporting System. [1990–2010]. *Neurology*. 2012;78.
- Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of Myocardial Infarction and Stroke after Acute
 Infection or Vaccination. *The New England Journal of Medicine*. 2004;351:2611-2618.
- Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and
 presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-5684.
- Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse
 Event Reporting System, 1990-2016. *Journal of Allergy and Clinical Immunology*. 2019;143(4):1465-1473.
- 335 26. Donahue JG, Kieke BA, Lewis EM, et al. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human
 336 Papillomavirus Vaccine. *Pediatrics*. 2019;144(6).
- 337 27. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the
 338 Vaccine Safety Datalink. *Vaccine*. 2011;29(46).
- Renoud L, Khouri C, Revol B, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality
 Analysis Using the World Health Organization Pharmacovigilance Database. *JAMA Internal Medicine*. 2021;181(9):1243 1245.
- Wijnans L, Dodd CN, Weibel D, Sutrkenboom M. Bell's palsy and influenza(H1N1)pdm09 containing vaccines: A self controlled case series. *PLoS One*. 2017;12(5).
- 344 30. Pishko AM, Bussel JB, Cines DB. COVID-19 vaccination and immune thrombocytopenia. *Nature Medicine*. 2021;27(7):1145 345 1146.

- 346 31. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107:I-22-I-30.
- 347 32. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. *Blood.*2014;123(12):1794-1801.
- 349 33. Vickers ER, McClure DL, Naleway A, et al. Risk of venous thromboembolism following influenza vaccination in adults aged
 350 50 years and older in the Vaccine Safety Datalink. *Vaccine*. 2017;35(43):5872-5877.
- 34. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel
 coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*. 2020;18(4):844-847.
- 353 35. Pellegrino P, Carnovale C, Perrone V, et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse
 adverse events reporting systems. *PLoS One*. 2013;8(10).
- 355 36. Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 6 to 23 months. *Pediatrics*.
 2016;138(1).
- 357 37. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following
 358 Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013;31(40):4448-4458.
- 359 38. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national 360 influenza immunization program, United States, 1976–1977. *American Journal of Epidemiology*. 1979;110(2):105-123.
- 361 39. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. *British Journal of Clinical* 362 *Pharmacology*. 2003;55(1):107-111.
- 363 40. D'alò G, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization.
 364 *Journal of Preventive Medicine and Hygiene*. 2017;58(1):E13-E26.
- Baker MA, Baer B, Kulldorff M, et al. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young
 children: A self-controlled risk interval and cohort study with null results. *PloS Medicine*. 2019;16(7).
- Yung CF, Ma X, Cheung YB, Oh BK, Soh S, Thoon KC. Kawasaki Disease following administration of 13-valent
 pneumococcal conjugate vaccine in young children. *Scientific Reports*. 2019;9(1).
- Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MISC) guidelines; a Western New York approach. *Progress in Pediatric Cardiology* 2020.
- Kuntz J, Crane B, Weinmann S, Naleway AL, Team VSDI. Myocarditis and pericarditis are rare following live viral vaccinations in adults. *Vaccine*. 2018;36(12):1524-1527.
- Klein NP. Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and "head-to-head" product comparisons.
 2021; <u>https://stacks.cdc.gov/view/cdc/110921</u>.
- 46. Duffy J, Weintraub E, Vellozzi C, DeStefano F. Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United
 States. *Neurology*. 2019;83(20):1823-1830.
- Montplaisir J, Petit D, Quinn M, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009)
 pandemic influenza vaccine in Quebec. *PLoS One*. 2014;9(9).

- 379 48. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations:
 380 Systematic review and meta-analysis. *Sleep Medicine Reviews*. 2017;38:177-186.
- 49. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. *Lupus*.
 2009;18(13):1198-1204.
- Whitworth H, Sartain SE, Kumar R, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MISC. *Blood.* 2021;138(2):190-198.

Outcome	Age Group (years)	Care Setting	Clean Interval (days)*	Risk Interval (days)	Descriptive Analysis	Sequential Testing
	6 mos4/6 mos5				Yes	No
A outo muccondial information	5-17/6-17	TD	265	1 29 ^{22,23}	Yes	No
Acute myocardiar infarction	18-64	Ir	303	1-28	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5.				Yes	Yes
Apophylovic	5-17/6-17.		20	0 124,25	Yes	Yes
Anaphylaxis	18-64	IP, OP-ED	50	0-1	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Appondicitie	5-17/6-17		265	1 4226,27	Yes	Yes
Appendicitis	18-64	IF, OF-ED	305	1-42	Yes	Yes
	65+				Yes	Yes
	6 mos4 /6 mos5				Yes	Yes
Ball's paley	5-17/6-17		183	1 4228,29	Yes	Yes
Den's paisy	18-64	II,01/1B	105	1-42	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Common site thrombosis with	5-17/6-17	[Definition below]**	365	1 28 ³⁰	Yes	Yes
thrombocytopenia	18-64		505	1-28	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Deep vain thromhosis	5-17/6-17		365	1 2031-33	Yes	Yes
Deep ven thromoosis	18-64	II,01/1B	505	1-28	Yes	Yes
	65+.				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Disseminated intravascular	5-17/6-17		365	1 28 ³⁴	Yes	Yes
coagulation	18-64	IF, OF-ED	365	1-28 ³⁴	Yes	Yes
	65+				Yes	Yes

386 Table 1. Health outcome definitions (settings, clean intervals, risk intervals), and analysis types

	6 mos4/6 mos5				Yes	Yes
Encephalitis/	5-17/6-17	-	192	1 4235	Yes	Yes
encephalomyelitis	18-64	IP	185	1-42	Yes	Yes
	65+	_			Yes	Yes
Eshella esimua	6 mos4/6 mos5		42	0.736	Yes	No
redfile seizures	5-17/6-17	IP, OP-ED	42	0-7	Yes	No
	6 mos4/6 mos5				Yes	Yes
Cuillein Domé cun dromo	5-17/6-17	ID mimory position only	265	1 4237,38	Yes	No
Guinani-Barre syndrome	18-64	- IP- primary position only	303	1-42	Yes	Yes
	65+	_			Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Hemorrhagie stroke	5-17/6-17	ID	265	1 28 ^{22,23}	Yes	No
nemormagic stroke	18-64		303	1-28	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
Immune thrombocytopenia	5-17/6-17	IP (primary diagnosis	265	1 4239,40	Yes	Yes
	18-64	only)	505	1-42	Yes	Yes
	65+				Yes	Yes
Kawacaki dicasa	6 mos4/6 mos5		265	1 2841,42	Yes	No
Kawasaki uisease	5-17/6-17		303	1-20	Yes	No
	6 mos4/6 mos5				Yes	No
Multisystem inflammatory syndrome	5-17/6-17		365	1 4243	Yes	No
wuitisystem mitaminatory syndrome	18-64		505	1-42	Yes	No
	65+.				Yes	No
	6 mos4/6 mos5.				Yes	Yes
	5-17/6-17				Yes	Yes
Myocarditis/	18-35	IP, OP/PB	365	1-7 ^{10,44}	Yes	Yes
pericarditis	18-64	IP, OP-ED	303	1-21 ⁴⁵	Yes	Yes
	36-64				Yes	Yes
	65+				Yes	Yes
Narcolepsy	6 mos4/6 mos5	IP, OP/PB	365	$1-42^{46-48}$	Yes	No

	5-17/6-17				Yes	Yes
	18-64			-	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
	5-17/6-17		275	1 20 ^{22,23}	Yes	Yes
Non-nemorrhagic stroke	18-64		365	1-28	Yes	Yes
	65+				Yes	Yes
	6 mos4/6 mos5				Yes	Yes
	5-17/6-17		275	4 2031-33	Yes	Yes
Pulmonary embolism	18-64	IP	365	1-28	Yes	Yes
	65+				Yes	Yes
	6 mos1				Yes	Yes
Seizures/	2-4 /2-5	IP, OP-ED	42	0-7 ³⁶	Yes	Yes
convulsions	5-17/6-17				Yes	Yes
	6 mos4/6 mos5				Yes	No
	5-17/6-17			49	Yes	No
Transverse myelitis	18-64	IP, OP-ED	365	1-42	Yes	Yes
	65+			_	Yes	Yes
	6 mos4/6 mos5				Yes	No
Unusual site thrombosis with	5-17/6-17			50	Yes	No
thrombocytopenia	18-64	[Definition below]**	365	1-28	Yes	Yes
	65+				Yes	Yes

387

Definitions: Clean interval is defined as an interval used to define incident outcomes where an individual enters the study cohort only if the outcome did not occur during that

388 interval. Risk interval is defined as an interval during which occurrence of the outcome will be included in the analysis.

389 Acronyms: IP - inpatient; OP-ED - outpatient emergency department; OP/PB outpatient & professional

390 * References for the clean interval could not be located in the literature and are based on clinician input

391 ** Common site thrombosis with thrombocytopenia and unusual site thrombosis with thrombocytopenia are combined outcomes consisting of a thrombotic event (made up of

392 other events such as acute myocardial infarction, deep vein thrombosis etc.,) and a thrombocytopenia event (defined in the IP, OP/PB setting). The overall setting definition for 393 each outcome depends on individual setting definitions for each of these components

394

396 Table 2. Characteristics of the population vaccinated with bivalent COVID-19 mRNA vaccines aged 6 months-64 years in CVS Health, Carelon

397 Research, and Optum Databases; aged \geq 65+ years in Medicare Database

Patient Characteristics	Any Bivalen	t COVII	D-19 mRNA V	accine	В	NT162b	2 Bivalent		mRNA-1273.222			
	Commer Databas	cial ses	Medica	re	Commer Databas	cial ses	Medica	re	Commer Databas	cial ses	Medicare	
	N	%	Ν	%	N	%	Ν	%	Ν	%	Ν	%
Total	5,498,556	100	8,380,283	100	3,769,301	100	4,869,360	100	1,729,255	100	3,510,923	100
Age at Vaccine Administration (year	rs)	1				1						
6 mos4	33,051	0.6			33,051	0.9						
5-11	234,201	4.3			234,201	6.2						
6 mos5	23,864	0.4							23,864	1.4		
6-11	21,719	0.4							21,719	1.3		
12-17	329,297	6.0			301,069	8.0			28,228	1.6		
18-25	454,374	8.3			319,187	8.5			135,187	7.8		
26-35	872,613	15.9			579,921	15.4			292,692	16.9		
36-45	1,026,398	18.7			684,872	18.2			341,526	19.7		
46-55	1,128,330	20.5			748,022	19.8			380,308	22.0		
56-64	1,374,709	25.0			868,978	23.1			505,731	29.2		
65-74			4,414,887	52.7			2,544,098	52.2			1,870,789	53.3
75-84			2,937,151	35.0			1,699,813	34.9			1,237,338	35.2
85+			1,028,245	12.3			625,449	12.8			402,796	11.5
Missing/ Unknown	0	0.0	0	0.00	0	0.0	0	0.0	0	0.0	0	0.0
Sex												
Female	2,973,454	54.1	4,760,468	56.8	2,039,091	54.1	2,784,173	57.2	934,363	54.0	1,976,295	56.3
Male	2,522,429	45.9	3,619,815	43.2	1,728,476	45.9	2,085,187	42.8	793,953	45.9	1,534,628	43.7
Missing/ Unknown	2,673	0.0	0	0.0	1,734	0.0	0	0.0	939	0.1	0	0.0
Urban/Rural												

Rural	270,566	4.9	1,437,843	17.2	155,304	4.1	706,057	14.5	115,262	6.7	731,786	20.8
Urban	5,224,680	95.0	6,906,602	82.4	3,611,592	95.8	4,143,587	85.1	1,613,088	93.3	2,763,015	78.7
Missing/ Unknown	3,310	0.1	35,838	0.4	2,405	0.1	19,716	0.4	905	0.1	16,122	0.5
Nursing Home												
Residency	1	T			0		1				1	
Nursing Home			162,676	1.9			114,823	2.4			47,853	1.4
Non- Nursing Home			8,217,607	98.1			4,754,537	97.6			3,463,070	98.6
HHS Region**												
Region 1	415,184	7.6	636,543	7.6	260,059	6.9	375,493	7.7	155,125	9.0	261,050	7.4
Region 2	717,615	13.1	772,359	9.2	497,768	13.2	445,935	9.2	219,847	12.7	326,424	9.3
Region 3	663,777	12.1	1,041,119	12.4	456,144	12.1	605,595	12.4	207,633	12.0	435,524	12.4
Region 4	700,716	12.7	1,436,145	17.1	484,902	12.9	780,141	16.0	215,814	12.5	656,004	18.7
Region 5	840,248	15.3	1,510,948	18.0	594,476	15.8	933,502	19.2	245,772	14.2	577,446	16.4
Region 6	335,791	6.1	712,875	8.5	222,060	5.9	376,103	7.7	113,731	6.6	336,772	9.6
Region 7	196,416	3.6	486,163	5.8	143,920	3.8	309,893	6.4	52,496	3.0	176,270	5.0
Region 8	243,198	4.4	308,916	3.7	178,681	4.7	209,853	4.3	64,517	3.7	99,063	2.8
Region 9	1,162,526	21.1	1,076,085	12.8	763,870	20.3	586,787	12.1	398,656	23.1	489,298	13.9
Region 10	220,579	4.0	391,565	4.7	165,541	4.4	241,908	5.0	55,038	3.2	149,657	4.3
Missing/ Unknown	2,506	0.0	7,565	0.1	1,880	0.0	4,150	0.1	626	0.0	3,415	0.1
Concomitant Vaccin	ation Status											
Influenza (Same Day)	2,223,077	40.4	2,764,112	33.0	1,545,503	41.0	1,720,039	35.3	677,574	39.2	1,044,073	29.7
Influenza (+/- 42 days)*	3,391,431	61.7	6,005,972	71.7	2,325,523	61.7	3,539,611	72.7	1,065,908	61.6	2,466,361	70.2

399 *Relative to bivalent COVID-19 mRNA vaccination date to align with broadest adverse event-specific risk interval

400 **Health and Human Services (HHS) regions are designated by the U.S. HHS Department to serve state and local organizations. Information on individual U.S. states and

401 territories included in each region is linked.

402 Data cuts: CVS Health (2/28), Carelon (3/4), Optum (7/8), Medicare (4/22)



408

404 Figure 1. Pattern of vaccination trends in vaccine administrations of bivalent COVID-19 mRNA vaccines, August 2022 - April 2023 by vaccine brand
 405 and database



medRxiv preprint doi: https://doi.org/10.1101/2024.01.24.24301676; this version posted January 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

409 Figure 2. Pattern of bivalent COVID-19 mRNA vaccines uptake August 2022- July 2023 by age group and database



- 412
- 413

			BNT162b2 Bivalent						mRNA 1273.222						
Outcome	Age Group of Interest		Commercial Databases			Medicare		Com	mercial Data	bases	Medicare				
	(years)	No. Cases	Person- Years	Signal ⁺	No. Cases	Person- Years	Signal ⁺	No. Cases	Person- Years	Signal ⁺	No. Cases	Person- Years	Signal ⁺		
Acute	18-64	173	183,346	No				111	95,413	No					
infarction	65+				1,391	185,695	No				847	124,521	No		
	6 mos4 /6 mos5	0	169	NA				0	123	NA					
Anaphylaxis	5-17/6-17	0	2,879	NA				0	269	NA					
	18-64	<11	17,190	Yes*				<11	8,895	Yes*					
	65+				<11	26,573	No				<11	19,167	No		
Appendicitis	6 mos4 /6 mos5	0	1,650	NA				<11	1,432	NA					
	5-17/6-17	57	46,901	No				<11	4,350	NA					
	18-64	270	271,731	No				153	141,412	No					
	65+				378	520,510	No				286	377,255	No		
	6 mos4 /6 mos5	0	2,591	NA				<11	1,964	NA					
Bell's palsy	5-17/6-17	19	54,336	No				<11	5,041	NA					
	18-64	313	319,957	No				147	166,052	No					
	65+				853	434,115	No				793	389,836	No		
Common site thrombosis with thrombocytop	6 mos4 /6 mos5 **	0	603	NA				0	568	NA					
	5-17/6-17	<11	32,218	NA				0	3,000	NA					
enia	18-64	38	185,056	No				17	96,260	No					
enia	65+				680	281,427	No				597	248,391	No		

Table 3. Sequential testing results in population vaccinated with bivalent COVID-19 mRNA vaccines

	6 mos4 /6 mos5	0	1,308	NA				0	1,113	NA			
Deep vein thrombosis	5-17/6-17	<11	32,229	NA				0	2,998	NA			
	18-64	403	184,442	No				203	95,926	No			
	65+				1,641	207,772	No				1,055	141,714	No
	6 mos4 /6 mos5	0	1,112	NA				0	966	NA			
Disseminated	5-17/6-17	<11	31,587	NA				0	2,934	NA			
coagulation	18-64	<11	182,927	No				<11	95,193	No			
	65+				72	348,559	No				47	252,617	No
	6 mos4 /6 mos5	0	1,984	NA				0	1,535	NA			
Encephalitis/ encephalomye	5-17/6-17	0	52,101	NA				0	4,806	NA			
litis	18-64	<11	311,472	NA				<11	161,738	NA			
	65+				52	537,826	No				37	388,869	No
Guillain-	6 mos4 /6 mos5	0	1,579	NA				0	1,377	NA			
Barré syndrome	18-64	<11	270,776	No				<11	140,894	NA			
	65+				21	518,627	No				11	375,854	No
Hemorrhagic	6 mos4 /6 mos5	<11	1,222	NA				0	1,049	NA			
stroke	18-64	30	184,170	No				15	95,832	No			
	65+				555	348,265	No				356	252,438	No
Immune	6 mos4 /6 mos5 ***	0	320	NA				0	323	NA			
enia	5-17/6-17	0	47,461	NA				0	4,411	NA			
	18-64	<11	273,946	No				<11	142,520	No			

	65+				42	521,851	No				23	378,240	No
	6 mos4 /6 mos5	0	381	NA				0	319	NA			
Myocarditis/P	5-17/6-17	<11	8,295	NA				0	773	NA			
7 day risk window, all	18-35	<11	11,832	Yes				<11	5,618	NA			
settings)	18-64	26	47,204	No				13	24,550	No			
	36-64	17	35,371	No				<11	18,932	No			
	65+				72	87,542	No				51	63,449	No
	6 mos4 /6 mos5	0	1,077	NA				0	905	NA			
Myocarditis/P ericarditis (1-	5-17/6-17	<11	24,533	NA				0	2,283	NA			
21 day risk	18-35	19	35,061	No				<11	16,641	No			
window, all settings)	18-64	61	140,157	No				30	72,891	No			
	36-64	42	105,096	No				23	56,250	No			
	65+				253	261,992	No				149	189,899	No
	6 mos4 /6 mos5	0	357	NA				0	300	NA			
	5-17/6-17	<11	8,220	NA				0	767	NA			
Myocarditis/P ericarditis (1- 7 day risk	18-35	<11	11,773	NA				<11	5,591	NA			
window, IP/OP-ED)	18-64	<11	47,003	No				<11	24,450	NA			
	36-64	<11	35,230	NA				<11	18,859	NA			
	65+				27	87,613	No				16	63,497	No
Myocarditis/P ericarditis (1-	6 mos4 /6 mos5	0	993	NA				0	841	NA			
21 day risk window,	5-17/6-17	<11	24,277	NA				0	2,258	NA			

IP/OP-ED)	18-35	<11	34,823	No				<11	16,538	NA			
	18-64	13	139,362	No				<11	72,503	No			
	36-64	<11	104,539	No				<11	55,964	No			
	65+				75	262,202	No				42	190,042	No
	5-17/6-17	<11	47,933	NA				<11	4,454	NA			
Narcolepsy	18-64	140	275,418	No				67	143,284	No			
	65+				181	521,422	No				149	377,965	No
	6 mos4 /6 mos5	0	1,177	NA				0	1,012	NA			
Non- hemorrhagic	5-17/6-17	<11	31,792	NA				0	2,953	NA			
stroke	18-64	70	183,450	No				37	95,472	No			
	65+				871	186,210	No				900	198,968	No
Dulmonomy	5-17/6-17	0	32,099	NA				0	2,987	NA			
embolism	18-64	57	184,601	No				29	96,041	No			
	65+				767	290,496	No				630	249,022	No
	6 mos1	<11	274	NA				<11	160	NA			
Seizures/Con vulsions	2-4/2-5	0	373	NA				0	311	NA			
	5-17/6-17	17	11,374	No				<11	1,061	NA			
Transverse	18-64	<11	272,051	No				0	141,575	NA			
myenus	65+				11	519,838	No				<11	376,755	No
Unusual site thrombosis with	18-64	<11	183,537	NA				<11	95,512	NA			
thrombocytop enia	65+				42	347,927	No				13	252,150	No

Counts less than 11 have been masked/suppressed

NA indicates that for the outcome and age group no testing was initiated due to case counts < 3.

"--" indicates that the outcome and age group combination did not apply to a given database(s).

Acronyms: IP - inpatient, OP-ED - outpatient emergency department, OP/PB outpatient & professional

⁺ Indicates whether or not a statistical signal was observed in the database(s) for the outcome and age group.

*Signal observed in Carelon database, only

**Sequential testing not conducted in Optum database

***Sequential testing conducted in Carelon database, only

medRxiv preprint doi: https://doi.org/10.1101/2024.01.24.24301676; this version posted January 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

415 Table 4. Frequency of vaccine doses and outcomes among outcomes only descriptively monitored

			BNT162b	2 Bivalent		mRNA 1273.222					
Outcome	Age Group of Interest	Comm Data	nercial bases	Med	icare	Comm Data	nercial bases	Med	icare		
	(years)	No. Cases	No. Doses	No. Cases	No. Doses	No. Cases	No. Doses	No. Cases	No. Doses		
Acute myocardial	6 mos4 / 6 mos5	0	20,857			0	17,361				
infarction	5-17/6-17	0	436,784			0	40,746				
Common site thrombosis with thrombocytopenia	6 mos4 / 6 mos5 *	0	9,764			0	7,551				
Febrile seizures	6 mos4 / 6 mos5	<11	31,571			<11	22,990				
	5-17/6-17	<11	525,424			<11	49,056				
Guillain-Barré syndrome	5-17/6-17	0	436,785			0	40,746				
Hemorrhagic stroke	5-17/6-17	<11	436,775			0	40,746				
Immune thrombocytopenia	6 mos4 / 6 mos5 **	0	15,111			0	12,432				
Kawasaki disease	6 mos4 / 6 mos5	0	20,837			0	17,348				
	5-17/6-17	<11	436,688			<11	40,736				
Multisystem	6 mos4 / 6 mos5	0	20,856			0	17,359				
inflammatory	5-17/6-17	0	436,772			0	40,745				
syndrome	18-64	0	2,478,389			0	1,288,891				
	65+			<11	4,574,507			0	3,315,135		
Narcolepsy	6 mos4 / 6 mos5	0	20,856			0	17,361				
Pulmonary embolism	6 mos4 / 6 mos5	0	20,857			0	17,361				
Transverse	6 mos4 / 6 mos5	0	20,856			0	17,361				
myenus	5-17/6-17	<11	436,784			0	40,746				
Unusual site thrombosis with	6 mos4 / 6 mos5	0	20,857			0	17,361				
thrombocytopenia	5-17/6-17	0	436,784			0	40,746				

416 Counts less than 11 have been masked/suppressed.

417 "--" indicates that the outcome and age group combination did not apply to a given database(s).

418 *Contain counts from Optum, only

419 **Contain counts from CVS Health and Optum, only

420 Data cuts: CVS Health (2/28), Carelon (3/4), Optum (7/8), Medicare (4/22)